The toxicity and safety of nimotuzumab have been assessed in several pre-clinical and clinical studies wherein it was noticed that side effects usually caused by EGFR inhibitors, especially rashes and other skin toxicities,  were negligible.  Scientists have hypothesized that this is because nimotuzumab binds only to cells that express moderate to high EGFR levels.<ref name=mAbs2009/>
